Elucidating Novel AAV/SERCA2a Gene Therapy for the Treatment of Duchenne Cardiomyopathy
Time: 9:30 am
day: Conference Day 1
Details:
- Cardiomyopathy associated with Duchenne continues to cause morbidity and mortality in affected patients
- Directed gene therapy to treat cardiomyopathy has not been available yet
- Delivery of AAV/SERCA2a in patients with cardiomyopathy is a promising strategy for improving the lives of patients in need
